InvestorsHub Logo
Followers 7
Posts 564
Boards Moderated 0
Alias Born 08/27/2014

Re: Biobillionair post# 32973

Wednesday, 08/27/2014 12:10:54 PM

Wednesday, August 27, 2014 12:10:54 PM

Post# of 425795
I don't think the anchor market has changed at all, last I heard it was still around 40M patients. If amarin gets expanded label, then it seems that its all theirs for the taking except for off label scripts involving Lovaza and generic. Back to pre adcom level immediately is my take with a positive FDA outcome. Not sure NCE will have that much impact at this late stage, but patent infringement fight with AZN will prove patent strength, and NCE loses its significants....all IMHO of course!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News